TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox

EDINBURGH, Scotland, Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox. TCB008 is an allogeneic unmodified cell therapy that is made up of activated and expanded gamma delta T (GDT) ce ...